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We have recently cloned and sequenced two genomes of defective interfering (DI) Semliki Forest virus (SFV), DI-6 (2146
nt), and DI-19 (1244 nt). These are similar in that both contain two large central deletions (encompassing the 59 part of the
nsP1 gene and the 39 part of the nsP2 gene and all of the structural genes), and all the sequence of the latter is represented
in the genome of SFV DI-6. RNA was transcribed from both and transfected into SFV-infected BHK-21 cells. RT–PCR analysis
of tissue culture fluid harvested 18 h after transfection suggested that SFV DI virions had been rescued from the cloned
genomes. Unlike the genomes of noncloned DI SFV, these genomes bred true for at least 7 serial passages. Cloned DI-6 and
DI-19 viruses interfered to a similar extent with the multiplication of SFV in cultured cells, but only DI-19 protected mice from
a lethal intranasal dose of SFV. Further investigation by RT–PCR analysis showed that DI-19 but not DI-6 genomes were
replicated in mouse brain after direct intracerebral injection of DI virus together with an excess of infectious helper SFV. Thus
the replication and hence antiviral activity of two closely related DI SFV genomes appears to be exquisitely sequence specific
and cell specific. These findings mark a significant step on the way to using DI genomes as antivirals and also may explain
why so few animal-protecting DI viruses have been identified. © 1998 Academic Press
INTRODUCTION
Defective interfering (DI) viruses have been described for
most families of viruses (reviewed by Perrault, 1981; Dim-
mock, 1991; Roux et al., 1991; Holland, 1990). They possess
a genome that is a deleted form of the standard (infectious)
virus genome and thus require standard virus to provide
replicative and encapsidative proteins for propagation. In
addition, they have the property of interfering with the mul-
tiplication of standard virus. DI viruses are generated on
serial passage at both low and high multiplicities of infec-
tion of standard virus in tissue culture, but because they are
unable to replicate autonomously, their propagation is
favoured by high multiplicity infection. Although by defini-
tion all DI viruses have the property of being able to inter-
fere with the multiplication of standard virus in cell culture,
in only a few systems has protection of animals from infec-
tion in vivo been solidly demonstrated (SFV: reviewed by
Barrett and Dimmock, 1986; vesicular stomatitis virus (VSV):
Doyle and Holland, 1973; Holland et al., 1976; Jones and
Holland, 1980; Fultz et al., 1982; Cave et al., 1985; influenza
A virus: reviewed by Dimmock, 1996).
Recently we described two DI SFV genomes (DI-6: 2146
nts and DI-19: 1244 nts) that were obtained from a cell
culture-generated DI preparation that was able to protect
mice from a lethal infection with SFV. These genomes were
derived from three noncontiguous regions of the SFV ge-
nome: the 59 untranslated region and the nsP1 coding
region, part of the nsP2 coding region, and the 39 untrans-
lated region (Thomson and Dimmock, 1994; see Fig. 1). In
addition to having a similar basic structure, all the se-
quence of DI-19 is present in DI-6. In contrast to clones of
DI-301 and DI-309 viruses (Lehtovaara et al., 1981, 1982), our
clones did not possess extensive repeats or sequence
rearrangements and were thought to be full-length DI ge-
nomes. Because previous work showed that DI SFV prep-
arations produced by serial passage of SFV in tissue cul-
ture are biologically and physically heterogeneous (Ka¨a¨ri-
a¨inen et al., 1981; Barrett et al., 1984a), DI genomes were
cloned with a view to regenerating naturally occurring DI
viruses that could be defined on the basis of their constit-
uent RNA sequences and hence be used to study se-
quence–function relationships.
In this report we show that molecularly cloned prepa-
rations of SFV DI-6 and DI-19, generated by transcription
and transfection of transcripts into SFV-infected cell
lines, were stable on serial passage and interfered with
the propagation of standard virus in cell lines. However,
only DI-19 protected mice from an otherwise lethal intra-
nasal infection of the central nervous system with a
highly neurovirulent strain of SFV. Failure of DI-6 to pro-
tect mice was probably due to its inability to be repli-
cated in brain, even after direct intracerebral injection
with an excess of infectious virus.
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RESULTS
Rescue and passage of pSFVDI-6 and pSFVDI-19
transcripts as virions
pSFVDI-6 and pSFVDI-19 were linearised at the 39
termini with NcoI and transcribed with T3 RNA polymer-
ase. This yielded RNAs of 2.1 and 1.2 kb, respectively.
Transcripts were not polyadenylated and had an addi-
tional guanylate residue at the 59 terminus as a conse-
quence of the promoter used. RNA transcripts were
capped with methylated diguanosine triphosphate, al-
though subsequent experiments found this to be unnec-
essary. Transcripts were transfected into BHK-21 cells
which had been infected previously with SFV. After a
single passage, RNAs of the same length as the DI-6 and
DI-19 transcripts were detected in tissue culture fluid by
RT–PCR. This and a later DI-19 passage is shown in Fig.
2. Faint 0.6- and 1.1-kbp products were also observed
after RT–PCR amplification of tissue culture fluid contain-
ing SFV, probably resulting from nonspecific binding of
the 59 primer to viral RNA. They were not seen if a primer
specific for a region just within the 59 terminus of the SFV
genome was used instead (data not shown).
After transfection of DI-19 RNA, a single RNA species
of the expected size of 1.2 kb was found to persist in the
virus population through at least 7 passages of tissue
culture fluid containing putative DI virus and SFV (Fig.
3a). The genome of DI-6 (2.1 kb) was similarly stable
(data not shown). These data indicate successful rescue
of the original RNA transcripts into DI virus particles and
their propagation without the generation of any other DI
genomes. RT–PCR products all had the same restriction
fragment patterns after digestion with AccI (Fig. 3b).
These were also similar to the restriction pattern of the
pSFVDI clone except for the absence of the 0.3-kbp
band. The latter is derived from the 39 terminus of the
clone and is included in the 3.0-kbp band of mainly
vector sequence. Northern blot analysis of RNA ex-
tracted from passage 3 of SFV and DI-19 was performed
using a RNA2 probe transcribed from pSFVDI-6 and
FIG. 1. Comparison of pSFVDI-6 and pSFVDI-19 with the SFV genome (Thomson and Dimmock, 1994). Both clones have parts of the genes encoding
nsP1 and nsP2. The top numbers in pSFVDI-6 and pSFVDI-19 refer to the nucleotide position in the DI sequence. The bottom numbers refer to the
corresponding nucleotide in the SFV genome. In pSFVDI-6, the region 1791–1814 could not be assigned to SFV, and the region 1828–1879 is an
imperfect repeat of 1880–1930.
FIG. 2. Transfection of RNA transcribed from pSFVDI-6 and pSFVDI-19
into SFV-infected BHK-21 cells. pSFVDI-6 and pSFVDI-19 were transcribed
with T3 RNA polymerase and approximately 20 mg RNA transfected by
electroporation into BHK-21 cells previously infected with 10 PFU/cell SFV.
Culture medium was harvested after 18 h and was passaged serially in
BHK-21 cells. RNA was detected in culture medium by RT–PCR with
primers specific for the termini of the SFV genome. The RT–PCR products
from DI-19 after 3 passages in BHK-21 cells (p3) and DI-6(p1), of 1.2 and 2.1
kbp, respectively, corresponded to the sizes of the two cloned molecules.
The faint 1.1-kbp band obtained from the SFV sample and DI-6 was derived
through nonspecific hybridisation of the primers to SFV sequences (see
text). The SFV genome is too large to be amplified by the RT–PCR method
used. M, marker DNA.
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showed that only virion RNA and an RNA of 1.2 kb were
present. A similar analysis of passage 3 of SFV and DI-6
using the same probe showed the expected 2.1-kb band
(data not shown).
Rescue and passage of uncloned transcripts from
RNA extracted from uncloned DI-p7 yields an
evolving population of DI SFV genomes
DI SFV DNA sequences (DI-p7 transcript) were ob-
tained by RT–PCR from RNA extracted from DI-p7 using
the primers 59SFV-T3 and 39SFV that are specific for the
termini of SFV. DI-p7 virus is the mouse-protecting tissue
culture preparation from which pSFVDI-6 and pSFVDI-19
were derived. The RT–PCR products obtained comprised
a predominant DNA species of 1.2 kbp and a minor one
of 2.1 kbp, which are equivalent in size to pSFVDI-19 and
pSFVDI-6, respectively. DI-p7 DNA has a terminal T3
promoter, and direct transcription with T3 polymerase
produced RNAs of 1.2 and 2.1 kb. These were transfected
into SFV-infected BHK-21 cells. Tissue culture fluid was
harvested at various passages after transfection for anal-
ysis of putative DI virus particles derived from trans-
fected RNA by RT–PCR. The predominant RT–PCR prod-
uct from passage 2 of DI-p7-transcript was 1.2 kbp, the
same size as that from DI-19 (Fig. 4a). After passage 3
(Fig. 4b) several DNA species, including those of 1.1, 1.2,
and 1.4 kbp, could be seen in contrast to the single
RT–PCR product of molecularly cloned DI-19.
Cloned DI-6 and DI-19 have interfering activity in
tissue culture
DI-6 and DI-19 were UV-irradiated under conditions
that just removed all infectivity. Table 1 shows that such
uvDI-6 and uvDI-19 have interference activities in both
BHK-21 and L929 cells that after 4 passages are compa-
rable with that of the uncloned DI-p7, with maximum
titres of approximately 1/100. DI virus preparations were
produced under standard culture and incubation condi-
tions, using the same quantity of input DI RNA; thus, any
FIG. 3. Detection of defective SFV RNA in passages 1 to 7 of DI-19. (a) Culture medium containing putative DI SFV derived from pSFVDI-19, produced
as described in Fig. 2, was serially passaged in BHK-21 cells. RNA was extracted from tissue culture fluid and amplified by RT–PCR using primers
specific for the termini of the SFV genome. DNA of 1.2 kbp was detected in the RT–PCR products derived from passages (p) 1 to 7 of DI-19. M, marker
DNA. (b) RT–PCR products derived from passages 2 to 7 of DI-19 were digested with AccI. The band patterns produced after agarose gel
electrophoresis were the same in all samples. Digestion of pSFVDI-19 with AccI is shown along side. The additional 3.0-kbp band comprised vector
sequences and included 0.3 kbp that derived from the 39 terminus of the clone.
FIG. 4. Transfection of RNA transcribed from DI-p7-derived RT–PCR
products into SFV-infected BHK-21 cells. DI SFV DNAs were amplified
from DI-p7 RNA using 59SFVT3 and 39SFV primers and RNA transcribed
using T3 polymerase. RNA was transfected into SFV-infected BHK-21
cells and culture medium harvested after 18 h and serially passaged in
BHK-21 cells. RNA was detected in culture medium by RT–PCR with the
primers specific for the termini of the SFV genome. In (a), the predom-
inant RT–PCR product from the second passage of the DI-p7-derived
preparation (DI-p7 transcript (p2)) is 1.2 kbp (arrowed) and is the same
size as that from DI-19(p2), but in lower quantities. In (b), arrows
indicate 1.1-, 1.2-, and 1.4-kbp products that appear on amplification of
RNA extracted from the third passage of the DI-p7-derived preparation
(DI-p7 transcript (p3)), in contrast to the single band from DI-19(p3).
There is a nonspecific RT–PCR product of 0.6 kbp (see text).
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differences in their titres reflect a combination of their
abilities to be propagated and to mediate interference.
Table 1 also shows that the preparation derived by RT–
PCR and transcription from the uncloned DI-p7 (DI-p7
transcript) (see above) interfered poorly here and at other
passage levels (data not shown) compared with the DI
SFV preparations derived from the molecular clones. As
a control, SFV4 derived from the infectious clone was
passaged in parallel with the cloned preparations of DI
SFV. In contrast with uvDI-6 and uvDI-19, interference
was not observed until 4–6 passages after transfection
and did not reach maximum titre until passage 7. The
possibility that the induction of interferons by UV-irradi-
ated DI-6 and DI-19 viruses contributed to interference
was not investigated. However, no interferons were
found in earlier studies when cells were inoculated with
noncloned DI SFV or DI SFV 1 SFV or when the effects
of putative interferons on interferon-sensitive heterolo-
gous viruses were examined in mice co-inoculated with
noncloned DI SFV or DI SFV 1 SFV (Dimmock and
Kennedy, 1978; Barrett and Dimmock, 1984, 1986).
Molecularly cloned DI-19, but not DI-6, protected
mice from a lethal SFV infection and only DI-19
was replicated in the brain
Random-bred CFLP and CD1 and the inbred BALB/c
mice were protected from a lethal intranasal infection
with SFV by administration of DI-19 (Table 2). Protected
mice showed no clinical signs and were indistinguish-
able from noninfected mice for the whole duration of the
experiment. At around 1 month after infection, they had
developed no protective immunity to homologous chal-
lenge with 100 LD50 (data not shown). Thus DI-19 resem-
bles the uncloned DI SFVp4, rather than DI SFVp13a that
left mice solidly immune (Barrett and Dimmock, 1984).
Nonprotected mice developed the same disease with the
same time span as infected controls. Inactivation of the
DI genome with BPL or prolonged UV irradiation abro-
gated protection, showing that protection required an
active DI genome and was not mediated by DI virus
competing for cell receptors or stimulating host defence
responses. However, DI-6 gave no detectable protection
in any of the mouse strains, even though its interfering
ability in cell culture was not significantly different from
that of DI-19 according to the Mann–Whitney U test.
Possible reasons for this include the inability of DI-6 to
exert interfering activity in cells of the central nervous
system, the main target tissue of SFV, or failure to be
replicated in these cells. To test the latter, approximately
equal amounts of DI-6 and DI-19 virus, normalized by
reference to their interference titres, were mixed with 106
PFU SFV and injected directly into the right cerebral
hemisphere of CD1 and CFLP mice. No protection was
expected from infection with this very large dose of SFV
(106 intracerebral LD50), which was chosen to give max-
TABLE 2
Protection of Mice from a Lethal SFV Intranasal Infection by
Administration of Molecularly Cloned DI Virusa
Inoculum Mouse survival (%)
SFV DI preparation CFLP Balb/c CD1
1 None 0b 0 0b
1 uvDI-p7c 75 75 nd
1 BPL-uvDI-p7 0 0 nd
1 uvDI-19 71 88 67
1 BPL-uvDI-19 11 0 0
1 uvDI-6 0 0 0
1 BPL-uvDI-6 0 0 11
2 uvDI-p7 100 100 100
2 BPL-uvDI-p7 100 100 100
2 uvDI-19 100 100 100
2 BPL-uvDI-19 100 100 100
2 uvDI-6 100 100 100
2 BPL-uvDI-6 100 100 100
2 None 100 100 100
Note. nd, not done.
a All DI SFV preparations were UV-irradiated for 80 s to remove virus
infectivity but not cell culture-based DI-mediated interference. Mice
were inoculated intranasally under light ether anaesthesia 2 h before
infection with the DI virus preparation shown and then at 0 h with 10
LD50ts
1 SFV 1 DI SFV also intranasally. Infected groups consisted of
7–9 mice and noninfected control groups of 2–3 mice. Noninfected
mice inoculated with a variety of DI virus preparations showed no sign
of disease. Infected mice died at 5–6 days pi.
b 13% (1/8) CFLP and CD1 mice survived inoculation with SFV alone
and this value was subtracted from the number surviving inoculation
with SFV 1 uvDI SFV.
c DI-p7 is uncloned DI virus.
TABLE 1
Interference by DI SFV with the Multiplication of SFV












uvDI-p7 transcript 2 4
uvDI-SFV4 3 ,2
uvDI-SFV4 7 64
a DI-p7 is uncloned DI virus; DI-6 and DI-19 are molecularly cloned DI
viruses; DI-p7 transcript is DI virus produced by transcription and
transfection of the RT–PCR product derived from uncloned DI p7;
DI-SFV4 is DI virus obtained from the infectious clone. Each virus
preparation was UV-irradiated to remove infectivity, as indicated by the
prefix uv. Each well was inoculated with 10 TCID50 SFV. No CPE was
observed in wells inoculated with uvDI SFV alone.
b Titres are defined as the reciprocal of the highest dilution showing
no CPE. Assays were carried out in BHK cells, apart from those
denoted *, which were in L929 cells. The two cell lines gave similar
amounts of interference. Titres are the mean of 4 replicate assays.
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imum replication of DI virus. Using the primers 59SFV and
39SFV, a RT–PCR product of the size expected for DI-19
was first detected at 2 days pi. Data for the CD1 mice are
shown in Fig. 5. The RT–PCR band increased in intensity
at 3 days and declined by 4 days pi (data not shown).
Mice died on day 5. Brains injected with DI-6 1 SFV were
analysed in parallel but no evidence of replication was
found in either strain of mouse. The RT–PCR analysis
was repeated using 59SFV and the internal primer 594-ve
that give a product of 1229 bp with DI-6 RNA. This is
similar in size to DI-19 (1244 nt) and controls for any
affect that size difference between DI-6 and DI-19 RNAs
may have on the sensitivity of the assay. However, the
DI-6 samples again proved negative (data not shown).
Mice injected with DI-6 1 SFV also died on day 5,
demonstrating that virus replication was unaffected.
Clearly DI-6 was at a replicative disadvantage in mouse
brain compared to DI-19. This result was surprising as all
the sequence of DI-19 is present within that of DI-6
(Thomson and Dimmock, 1994). Possible reasons for the
apparent tissue-specific requirement for the replication
of the DI-6 genome are discussed below.
DISCUSSION
Following transcription of DI RNAs from pSFVDI-6 and
pSFVDI-19 and their transfection into SFV-infected cells,
interfering activity could be detected after 2 serial pas-
sages. In contrast, interfering activity was detected in
standard SFV preparations derived from the infectious
clone only after 4 to 6 passages (Table 1; data not
shown). The sizes of RT–PCR products, restriction anal-
ysis, and Northern blot analysis showed that these prep-
arations contained only the DI RNA expected. It is evi-
dent therefore that DI-6 and DI-19 possess sequences
required for propagation and interference in vitro and
therefore represent genuine DI genomes.
The genomes of cloned DI-6 and DI-19 viruses were
maintained stably through at least 7 passages of the DI
viruses without the appearance of any other detectable
DI genomes. Thus they neither appeared to evolve nor
allowed the establishment of other DI genomes de novo.
The stability of cloned defective RNA contrasts with the
instability on passage of the genomes derived by RT–
PCR from noncloned DI SFV-p7 (Fig. 4b). Such domi-
nance by a single DI genome has also been seen with DI
VSV (reviewed by Holland, 1990) and DI influenza virus
(reviewed by Nayak et al., 1989) and is of obvious prac-
tical importance in maintaining stocks of DI particles
containing only a single species of RNA. Restriction
analysis of the RT–PCR products of DI-6 and DI-19 de-
rived from serially passaged material suggested that the
cloned defective genomes did not alter during their prop-
agation in vitro. Analysis of DI-6 and DI-19 RNAs by
Northern blotting failed to reveal the presence of any
other DI RNA sequences (data not shown).
Although DI-6 and DI-19 stocks gave similar interfering
titres in BHK and L cells, only DI-19 protected mice from
lethal intranasal infection with a virulent strain of SFV.
SFV is highly tropic for the central nervous system and
after intranasal inoculation is thought to gain access to
the brain via the olfactory nerves (Dimmock and
Kennedy, 1978; Kaluza et al., 1987). SFV-infected mice
that were protected by administration of DI-19 showed
no sign of infection, as reported before with noncloned
DI-SFV, and those few mice that were not protected
showed exactly the same course of disease as infected
mice that received no DI virus (Barrett and Dimmock,
1984). The ability of both DI viruses to be replicated in the
brain was tested by direct intracerebral injection to-
gether with a very high dose of SFV (106 PFU or 106
intracerebral LD50). Only DI-19 could be detected by
RT–PCR. Poor detection of the larger DI-6 genome did
not appear to be the reason, as use of an internal primer
that reduced its RT–PCR product to the size of the DI-19
genome also failed to give a positive signal and, in any
case, DI-6 was easily detected in cell culture fluids with
terminal primers. Thus it is likely that DI-6 could not be
replicated in brain tissue. As both DI-6 and DI-19 were
cloned from the same stock of DI virus it is clear there-
fore that this stock was heterogeneous. Direct demon-
stration of a DI virus that interfered in cell culture but did
not protect mice is in agreement with the earlier failure to
consistently propagate mouse-protecting DI virus de-
spite the preparations having constant amounts of inter-
fering activity (Barrett et al., 1984a).
The explanation that DI-6 failed to replicate in mouse
brain has a number of implications. Amongst these is the
inference that the biological activity of DI viruses in vivo
is cell specific. Some cell lines are also restricted for DI
virus in that they fail to generate, propagate, or allow DI
FIG. 5. DI-19 RNA but not DI-6 RNA is replicated in mouse brain.
Mixtures of DI virus and SFV (1000 intranasal LD50) or DI virus alone
were injected intracerebrally (approximately 50 ml) into CD1 mice. DI-6
(passage 4) and DI-19 (passage 6) viruses had interference titres of
1/62 and 1/136, respectively (not significantly different by the Mann–
Whitney U test). RNA was extracted from brains at 3 days pi, and,
RT–PCR products were generated with 59SFV and 39SFV primers and
analysed by agarose gel electrophoresis. uvDI is a DI virus preparation
that has been UV-irradiated to remove virus infectivity but not DI virus
activity. BPL-uvDI-19 and BPL-uvDI-6 are DI preparations that were
treated with BPL to inactivate the DI genome.
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genomes to interfere (Perrault and Holland, 1972; Eaton,
1975; Holland et al., 1976, 1978; McLaren and Holland,
1974; Stark and Kennedy, 1978; Philips et al., 1980; Barrett
et al., 1981; Steacie and Eaton, 1984). In turn, this implies
that DI genomes that protect in vivo are best isolated
from the cell or tissue of interest and that attempts to
create protecting DI genomes by deletion of the infec-
tious genome are unlikely to be successful. Because
there is a clear distinction between the interfering activity
of DI genomes in vitro and in vivo, we suggest that those
that protect animals should be classified separately as
defective protecting (DP) genomes or virus. The demon-
stration of a DI genome that fails to protect animals in
vivo may go some way to explaining the paucity of such
systems, despite the abundance of DI viruses in vitro.
The reason that DI-6 and DI-19 can be replicated in
hamster (BHK) and mouse (L929) cells but not in mouse
brain is intriguing, as both have the same general ge-
nome structure, and all the sequence of DI-19 (1244 nts)
is contained within the genome of DI-6 (2146 nts: Thom-
son and Dimmock, 1994; Fig. 1). Also DI-6 has some
sequence peculiarities, as nts 1791–1814 could not be
assigned to the SFV genome, and the region 1828–1879
is an imperfect repeat of 1880–1930. The significance of
these sequences is not known. Clearly the genome of
DI-6 is viable in an appropriate cell background, and
both DI viruses have the same coat proteins as infec-
tious SFV. Thus it seems likely that the failure of DI-6
RNA to be replicated in brain resides in the DI-6 genome
sequence or conformation. It is possible that a product of
the nsP1 open reading frame or its fusion product with a
central fragment of nsP2 is responsible for the dominant
negative effect exerted by DI-19, but this seems unlikely,
as the same initial nsP1 sequence is present (in an
extended form) in DI-6, and it is not easy to reconcile this
with a cell-specific effect. An alternative hypothesis for
the observed cell specificity is that infectious virus and
DI-19 genomes interact successfully with cellular factors
in the brain, while DI-6 does not. Such cellular factors are
likely to be involved in the replication of viral RNAs and
contribute to the structure of the viral polymerase itself
(as found in other RNA virus systems: Dmitrieva et al.,
1979; Blumenthal and Carmichael, 1979; Baron and Bal-
timore, 1982; Dasgupta, 1983; Hey et al., 1987; Hayes and
Buck, 1990; David et al., 1992; Quadt et al., 1993; Shimizu
et al., 1994). The hypothesis can be tested both positively
and negatively by making chimeras of DI-6 and DI-19
RNAs and testing for the gain and loss, respectively, of
replicative ability in mouse brain.
Almost all viruses make DI genomes. The discovery
reported here of a molecularly cloned DI genome that
protects against a life-threatening virus infection, to-
gether with the demonstration that a (very similar) DI
genome is not protective under identical conditions, is a
significant step forward to understanding how to harness
this vast reservoir of natural antivirals against human
and other diseases of animals and plants. This particular
branch of intracellular immunization (Baltimore, 1988)
may become a reality after all.
MATERIALS AND METHODS
Cells
BHK-21 cells (clone 13-3P) and L929 cells were ob-
tained from the European Collection of Animal Cell Cul-
tures (CAMR, Porton Down, Wilts, UK) and grown as
monolayers by standard methods.
Virus
SFV (standard virus, strain ts1; Tan et al., 1969) was
propagated in BHK-21 cell monolayers. Cultures were
inoculated at a multiplicity of infection (M.O.I.) of 0.1 PFU
per cell and incubated for 18 h at 37°C. Tissue culture
fluid was harvested and clarified by low-speed centrifu-
gation and stored at 270°C. Stocks of SFV derived from
the full-length infectious clone pSP6-SFV4 were gener-
ated by transcription and transfection into BHK-21 cells,
as described by Liljestro¨m et al. (1991). Virus of the
second passage after transfection was used for propa-
gation of DI virus.
DI virus
Clones of DI genomes, pSFVDI-6 and pSFVDI-19, were
derived from a tissue culture preparation of DI SFV that
was produced by seven high multiplicity passages of
SFV in BHK-21 cells (DI-p7). Besides interfering with virus
multiplication in cell culture, this preparation was able to
protect mice against a lethal dose of SFV (Dimmock and
Kennedy (1978); Barrett and Dimmock, 1984). RNA was
extracted from DI-p7 and amplified by reverse transcrip-
tion and polymerase chain reaction (RT–PCR) with Taq
and primers specific for the termini of SFV (see below).
The 59 primer incorporated a promoter for T3 RNA poly-
merase (59SFV-T3) and the 39 primer incorporated the
restriction enzyme site NcoI (39SFV-Nco). These features
were designed to permit runoff transcription of RNA (see
below). The nucleotide overhang was removed with the
large fragment of DNA polymerase I (Klenow) and the
RT–PCR products cloned into the SmaI site of pUC13.
Two clones, pSFVDI-6 and pSFVDI-19, were sequenced
and the regions of the SFV genome from which these two
clones were derived are indicated in Fig. 1 (Thomson
and Dimmock, 1994). RNA transcribed from cloned DI
DNA was rescued as virus particles by transfection into
SFV-infected BHK-21 monolayers (see below). This DI
virus was subsequently passaged with exogenous SFV
added at a M.O.I. of 60. Culture fluids were collected
after 24 h at 37°C.
Infectivity titration
Virus was plaque assayed in BHK-21 cell monolayers
by incubating at 37°C for 48 h with an agar overlay
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containing 0.08% DEAE–dextran. Live cells were stained
with neutral red (0.01% (w/v) in PBS) for 2 h at 37°C.
Alternatively, infectivity was estimated by an endpoint
assay in BHK-21 or L cells in 96-well plastic plates (2 3
104 cells/well; Nunclon; Gibco UK, Ltd.). CPE was deter-
mined by light microscopy after 3 days and the TCID50
calculated according to the Spearman–Ka¨rber equation
(Rhodes and van Rooyen, 1968).
UV irradiation to inactivate infectious virus in DI virus
preparations
DI and infectious SFV cannot be physically separated,
so preparations were UV irradiated to remove most of the
infectivity but minimal amounts of DI activity (Dimmock
and Kennedy, 1978). DI viruses were irradiated in 1-ml
aliquots in a 5-cm petri dish for 40, 50, or 60 s, titrated in
cell culture, and inoculated intranasally into mice (see
below). The lowest UV dose that gave no detectable
infectivity was then used. One log10 PFU was inactivated
in about 8 s with the UV source employed (Gelman
Sciences, Northampton, UK). Interference was measured
(see below) after UV treatment, to compensate for differ-
ences in rates of inactivation that arise from the different
sizes of DI genomes.
Inactivation of DI RNA
The RNA component of DI virus was inactivated by
either prolonged UV irradiation for 5 min or 0.1% (v/v)
b-propiolactone (BPL grade II; Sigma) in a final concen-
tration of 0.05 M Tris–HCl (pH 7.5) for 12 h at 4°C (Barrett
et al., 1984b). BPL was removed by dialysis against PBS
overnight at 4°C and inactivation verified by testing for
interfering activity.
RNA extraction from tissue culture fluid
RNA was extracted from small volumes of tissue cul-
ture fluid (typically 75 ml) with an equal volume of 10 mM
Tris–HCl, pH 7.9, 350 mM NaCl, 10 mM EDTA, 7 M urea,
1% (w/v) SDS followed by phenol extraction.
RNA extraction from brain tissue
Mouse brains were removed from the animal, frozen in
dry ice, and stored at 270°C. These were then homoge-
nised in 4 M guanidinium isothiocyanate. Equal volumes
of phenol (heated to 60°), chloroform, and 0.1 M NaAc
(pH 5.2) were added to the brain lysate and mixed into a
single phase. The tubes were centrifuged at 650 g for 15
min and the supernatant was then reextracted. RNA was
precipitated with ethanol at 270°C and recovered by
centrifugation. The pellet was resuspended in distilled
water and incubated in proteinase K in proteinase K
buffer at 37°C for 20 min. This was extracted twice with
an equal quantity of phenol–chloroform at 60°C and
once with chloroform alone at room temperature. RNA
was again ethanol-precipitated, recovered by centrifuga-
tion, and resuspended in sterile distilled water.
Reverse transcription and polymerase chain reaction
For production of cDNA, RNA was reverse transcribed
and amplified by PCR in 100 ml reaction buffer (10 mM
Tris–HCl, pH 8.3, 50 mM KCl, 0.01% gelatine, 4.5 mM
MgCl2, 0.5 mM each dNTP, 2 U AMV reverse tran-
scriptase, 1.5 U Taq polymerase [Perkin–Elmer Cetus
(ILS Ltd.), London, UK], 0.1 mg each primer) and overlaid
with 100 ml paraffin. For analysis of DI SFV RNA, the
primers 59-ATG GCG GAT GTG TGA CAT ACA CGA C-39
(59SFV), and 59-GGA AAT ATT AAA AAC CAA TTG CAA
AAT AAA ATA-39 (39SFV), which were homologous to the
59 terminus and complementary to the 39 terminus of SFV
virion RNA, respectively, were used. To abrogate any
effect of the difference in size of DI genomes, 59SFV was
used in conjunction with the internal primer 59-ACG CGT
GCA ACG TCT GGA T-39 (594-ve), which is complemen-
tary to nts 2623–2641 of the virion positive strand. These
make 594- and 1229-bp products with DI-19 and DI-6
RNAs, respectively. For production of cDNA that could be
used as a template for RNA transcription, RNA was
amplified with a 59 primer that incorporated the T3 poly-
merase promoter (underlined) 59-GCA ATT AAC CCT
CAC TAA AGA TGG CGG ATG TGT GAC ATA CA-39
(59SFV-T3) and a 39 primer that incorporated a NcoI
restriction site (underlined) 59-TTC CAT GGG AAA TAT
TAA AAA CCA ATT CCA ATT GCA-39 (39SFV-Nco). For
analysis of DI SFV RNA from brain tissue, the primers
59SFV and 39SFV were used. Typical reaction times were
40 min at 42°C for reverse transcription followed by 30
cycles of 60 s at 93°C, of 60 s at 58°C, and of 80 s at
72°C. A final step of 5 min at 72°C was included before
cooling to 25°C. RT–PCR products were analysed by
electrophoresis on 1% (w/v) agarose gels.
Transcription and analysis of transcription products
Runoff, capped transcripts were made by linearising
DI SFV plasmid DNA with NcoI and then synthesizing
RNA at 37°C for 1 h with 20–50 U T3 RNA polymerase in
50 ml reaction buffer (40 mM Tris HCl pH 8.0, 8 mM
MgCl2, 2 mM spermidine-(HCl)3, 25 mM NaCl, 10 mM
dithiothreitol, 5 mM ATP 1 TTP 1 CTP, 2.5 mM GTP, 1
mM sodium m7G(59)pppG (Pharmacia Biosystems Ltd.,
Milton Keynes, UK), 10 U human placental RNase inhib-
itor, 1 mg template DNA). DNA was degraded prior to
transfection by incubation at 37°C for 10 min with 5 U
RNase-free DNase (Promega Ltd., Southampton, UK).
Transcribed RNA was analysed by electrophoresis on 1%
agarose gels after denaturation by glyoxal (see below;
McMaster and Carmichael, 1977). Transcription of pSP6-




For rescue of DI SFV transcripts into DI particles,
BHK-21 monolayers were first infected with 10 PFU SFV
per cell for 45 min at 25°C and electroporated with 20 ml
of transcription reaction (approximately 20 mg RNA) us-
ing a Gene Pulser apparatus (Bio-Rad) as described by
Liljestro¨m et al. (1991).
Northern blot analysis
RNA extracted from tissue culture preparations was
analysed by Northern blotting using standard methods.
Briefly RNA was denatured with 1.08 M glyoxal and 53%
dimethyl sulphoxide at 50°C for 60 min and then anal-
ysed by agarose gel electrophoresis (after McMaster
and Carmichael, 1977). The RNA was then transferred to
a hybridisation filter and fixed by exposure to UV light for
5 min. For a probe, pSFVDI-6 was cloned in a pBluescript
(KS1) vector (Stratagene, Cambridge, UK) and negative-
strand RNA was produced from this labelled with
[a-32P]UTP (Amersham Int., plc, Aylesbury, UK). This de-
tected DI and virion RNAs but not 26S mRNA.
Interference assay
This assay measured the ability of DI SFV to prevent
the cytopathic effect (CPE) caused by infectious virus.
L929 or BHK cell monolayers in 96-well plates (2 3 104
cells/well; Nunclon) were inoculated with 10 TCID50/well
SFV for 1 h at 37°C. The medium was then aspirated and
replaced with maintenance medium. UV-irradiated DI
SFV (see above) was then titrated on the plate in two-fold
serial dilutions. Plates were incubated at 37°C for 48–60
h and CPE assessed. Assays were performed in quadru-
plicate and the interference titre was calculated accord-
ing to the Spearman–Ka¨rber equation. Differences of
$fourfold were significant according to the Mann–Whit-
ney U or nonparametric test (Campbell, 1967).
Mouse experiments
Young adult 5-week-old male CFLP, CD1, or Balb/c
mice (B & K Universal Ltd., Grimston, Aldborough, Hull;
Harlan UK., Bicester, Oxon) were used for these experi-
ments. The virulent ts1 strain of SFV was titrated to
determine the PFU:LD50 ratio for intranasal inoculation of
each strain of mouse (Dimmock and Kennedy, 1978). One
intranasal LD50 contained approximately 10
3 PFU.
Groups of 10 mice were lightly anaesthetised with ether
and inoculated with 10 LD50 in 20 ml divided between
nostrils. Mice developed encephalitis and died in 5–6
days, and the LD50 was determined according to Spear-
man–Ka¨rber (Rhodes and van Rooyen, 1968). Clinical
signs of disease have been described by Barrett and
Dimmock (1984) and these varied in detail between both
individual animals and strains. Briefly these were first
apparent at 3 days pi and included malaise, random
walking, and hyperactivity. More severe clinical signs
developed and by 4 days pi these had extended to
circling and proceeded to immobility with or without
paralysis. All mice showed raised fur and a hunched,
though relaxed, posture. To determine its protective abil-
ity, mice were inoculated first with DI virus which had
been UV irradiated to remove virus infectivity (uvDI; see
above) and then 2 h later with a mixture of uvDI virus 1
10 LD50 SFV (Dimmock and Kennedy, 1978). DI viruses
were used before passage 7, up to which time DI ge-
nomes bred true (see Fig. 3), and were normalized by
interference titre. To control for protective host re-
sponses directed against viral protein and also the pos-
sibility of DI virus blocking virus-specific receptors, the
experiment was repeated with uvDI virus that had been
inactivated with BPL or by prolonged UV irradiation (see
above). Attempts to propagate DI virus in the brain were
made by intracerebral injection into the right cerebral
hemisphere of a mixture of DI virus and 106 intracerebral
LD50 of SFV (approximately 10
6 PFU, determined by titra-
tion as described for intranasal inoculation: unpublished
data). This very large dose of SFV was used to ensure
that DI virus had every chance of being replicated. These
mice died at 5 days pi. All animal experimentation fol-
lowed the guidelines laid down by the UK Coordinating
Committee for Cancer Research.
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